(Circulation. 2000;102:1342.)
© 2000 American Heart Association, Inc.
Editorial |
Targeting Pathological Remodeling
Concepts of Cardioprotection and Reparation
From the Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis.
Correspondence to Karl T. Weber, MD, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Room 353 Dobbs Research Institute, 951 Court Avenue, Memphis, TN 38163. E-mail KTWeber{at}utmem.edu
Key Words: Editorials • hypertrophy • hypertension • fibrosis • collagen • angiotensin
The myocardium is composed of cardiac myocytes, which are tethered within an extracellular scaffolding of fibrillar collagen. Myocytes are large; they occupy a major portion of tissue space. However, they number only a third of all cells in the myocardium; noncardiomyocytes constitute the remaining two-thirds of cells and include endothelial and vascular smooth muscle cells of the intramural coronary circulation and fibroblasts located in interstitial and perivascular spaces.1 2 Ventricular hypertrophy is based on the growth of cardiac myocytes, which may or may not be accompanied by other iterations in tissue structure. In athletes, the growth of muscular and nonmuscular compartments of the heart are proportionate; tissue homogeneity is preserved. Such adaptive hypertrophy contributes to enhanced cardiac performance.
The myocardial mass that accompanies exercise training is comparable to the left ventricular hypertrophy (LVH) seen in patients with essential hypertension of mild to marked severity.3 In hypertensive heart disease (HHD), however, tissue homogeneity gives way to heterogeneity because the disproportionate involvement of noncardiomyocyte cells accounts for the pathological remodeling of tissue structure.2 Fibroblasts, for example, contribute to a perivascular fibrosis of intramural arteries and arterioles, which over time extends into contiguous interstitial space. This perivascular/interstitial fibrosis is based neither on myocyte growth nor necrosis; it represents reactive fibrosis. Medial thickening of these vessels involves hypertrophy and/or hyperplasia of vascular smooth muscle cells.4 Microscopic scarring (a reparative fibrosis) replaces myocytes lost to necrosis (apoptosis is not followed by fibrosis). Together with the hypertrophy of left ventricular myocytes, these iterations in tissue structure in HHD create a pathological hypertrophy that predisposes to an enhanced risk of adverse cardiovascular events, including myocardial infarction, diastolic and/or systolic ventricular dysfunction, symptomatic heart failure, and arrhythmias.5 6 It is not the quantity, but rather the quality, of myocardium that distinguishes HHD from adaptive hypertrophy of the athlete.
Targeting Pathological Remodeling
Homeostasis can be defined as a state of equilibrium that exists between different yet interdependent elements or groups of elements in a living organism (eg, salt and water balance in circulatory homeostasis). Tissue homeostasis relates to a self-determination in cellular composition and structure based on cell differentiation, replication, and programmed cell death and a growth or regression in its structural protein scaffolding. Peptide, steroid, and/or amine molecules, produced locally, are involved in regulating these events. Circulating substances can also participate (vide infra).
The structural homogeneity of normal adult myocardium is
governed by a balanced equilibrium between stimulator and
inhibitor signals (Figure 1
)
that, respectively, regulate cell growth (and apoptosis) and
phenotype and metabolic behavior (eg,
collagen turnover). Stimulators include both locally produced and
circulating substances that gain access to interstitial
fluid to create a state designed for growth, which can result in the
adverse structural remodeling of cardiac tissue. This remodeling can
include the growth of cellular elements and the synthesis of structural
proteins. Stimulators are normally counterbalanced by
inhibitory signals, which have opposing effects on cells
and matrix turnover.
|
Stimulator overproduction is invoked after tissue injury and initially contributes to circulatory homeostasis; its effects include platelet aggregation, coagulation, vasoconstriction, increased heart rate, enhanced contractility, and urinary sodium retention. Stimulators include angiotensin II, aldosterone, endothelins, and catecholamines. Inhibitors have opposing biological actions. They include bradykinin, nitric oxide, prostaglandins, natriuretic peptides, and glucocorticoids. Through the biological economy of action, stimulators are involved in the subsequent phases of tissue repair (inflammation and fibrogenesis).
Loss of the reciprocal regulation that normally exists between
stimulator and inhibitor production (Figure 2) accounts for connective tissue
remodeling (reviewed in Reference 7 ). An excess of
stimulators, due either to absolute stimulator overproduction
or a relative overabundance due to a deficit in inhibitor
formation, can promote fibrosis and, thereby, pathological
hypertrophy. Local overproduction of
angiotensin II, for example, accompanies a large,
transmural anterior myocardial infarction and, through its regulation
of fibrogenic transforming growth factor-ß1
expression, it contributes to infarct scar formation and to an
interstitial fibrosis that appears remote to the infarct
site. Cardiac fibrosis can accompany a paucity of
inhibitors, such as occurs with an experimental
interference with nitric oxide formation and which, in turn, can be
prevented by the pharmacological blockade of angiotensin II
type 1 receptors.8 9 In mice with a genetically targeted
interruption of their B2 bradykinin receptors,
progressive perivascular fibrosis occurs in the intramural
coronary vessels.10
|
Fibrosis of the heart, including the ventricles and atria, and the systemic organs accompanies long-term elevations in circulating effector hormones of the renin-angiotensin-aldosterone system. This occurs when renal perfusion is impaired by heart failure or unilateral renal artery stenosis. Organ fibrosis likewise accompanies chronic mineralocorticoid excess (plus salt) due to adrenal adenoma or exogenous treatment with aldosterone or deoxycorticosterone (reviewed in Reference 2 ). Cardiac tissue homogeneity is preserved when the myocyte growth that appears in response to ventricular pressure or volume overload is not associated with the activation of the circulating renin-angiotensin-aldosterone system. Such adaptive hypertrophy accompanies chronic anemia, small arteriovenous fistula, atrial septal defect, and hyperthyroidism.2
Targeted Interventions: Protective and Reparative
The adverse structural remodeling of cardiac tissue seen in HHD represents a targeted goal of pharmacological intervention. In recognizing the differential regulation of myocyte and nonmyocyte compartments posed by hemodynamic and nonhemodynamic factors, respectively, it is possible to prevent adverse structural remodeling. A cardioprotective agent counteracts the disproportionate balance that exists between stimulators and inhibitors. Such cardioprotective strategies include the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II type 1 receptor antagonists, antagonists of endothelin A and B receptors, and aldosterone receptor antagonists. Those agents that promote an overabundance of inhibitors to counterbalance stimulators include ACE and endopeptidase inhibitors.
Reparation of pathological remodeling in HHD is a concept based on specifically targeting such remodeling with a pharmacological intervention that will reverse the growth-promoting state and regress existing abnormalities in tissue structure. A cardioreparative intervention induces a relative excess of inhibitors to promote the apoptosis of myofibroblasts and the regression of the adverse accumulation of matrix protein by proteolytic digestion. Such a strategy is intended to promote the regression of, and perhaps even normalize, abnormalities in tissue structure, thereby improving or even correcting associated functional derangements. In HHD, this concept focuses on a regression in fibrous tissue accumulation, with or without a reversal of cardiac myocyte hypertrophy. In achieving this end point, it may be possible to reduce the risk of adverse cardiovascular events. In the 21st century, it may not be tenable to simply reduce arterial pressure in individuals having HHD. Has the cardioreparative concept undergone experimental validation? Is it possible to regress fibrous tissue?
Cardioreparation: Proof of Concept
Type I collagen is the dominant fibrillar collagen of the myocardium. Its tensile strength, which approximates that of steel, resists tissue deformation. Active degradation of this fibrillar collagen by proteolytic enzymes, termed matrix metalloproteinases (MMPs), which normally reside in the myocardium in latent form, is involved in the appearance of such pathological deformations as infarct expansion, ventricular aneurysm, and myocardial rupture.1 Pathophysiological elevations in diastolic or systolic pressure alone will not physically disrupt fibrillar type I collagen. In the arrested heart, a distending pressure >100 mm Hg is required to break fibrillar collagen.11 An intraventricular pressure >500 mm Hg is needed to induce ventricular rupture in the beating heart.12
A reduction in arterial pressure in systemic hypertension will not promote the regression of established fibrosis, which consists predominantly of type I collagen. Biochemical degradation is required. Can this be accomplished by pharmacological intervention?
This question was addressed in 14-week-old male rats with genetic hypertension (SHR) and in which established LVH with perivascular/interstitial fibrosis was present, together with abnormal myocardial stiffness and impaired coronary vasodilator reserve to adenosine.13 Twelve weeks of treatment with an ACE inhibitor, given in either nondepressor or depressor dosages, was undertaken. Comparisons were then made with 26-week-old, sex-matched, untreated SHR and untreated, normotensive Wistar-Kyoto (WKY) controls. The following were observed in treated SHR: normalization of arterial pressure and regression of LVH with depressor dosage only; regression of morphometrically assessed perivascular and interstitial fibrosis with either dosage and normalization of myocardial stiffness; and reversal of intramural coronary artery medial thickening with normalization in arterial pressure, together with a restoration in vasomotor reactivity. This study demonstrated the feasibility of regressing established cardiac fibrosis using an ACE inhibitor in young adult SHR. It also provided further evidence regarding the functional significance of fibrosis in HHD, independent of myocyte hypertrophy.
It remained to be determined whether such treatment would also prove effective when cardiac fibrosis was more advanced and whether the regression in fibrosis involved MMPs. These questions were addressed in 78-week-old male SHR with advanced HHD using 8 months of treatment with an oral ACE inhibitor that was given in depressor dosage.14 Comparisons were made with untreated age- and sex-matched SHR and with treated and untreated WKY controls. The following were observed in 110-week-old treated SHR: normalization in arterial pressure and complete reversal of LVH; a reduction in established cardiac fibrosis, with improvement in diastolic stiffness and prevention of the impaired systolic function that appeared in untreated SHR; and an increase in tissue MMP-1 activity (collagenase) with treatment, which was not seen in untreated or treated WKY. This study further demonstrated the feasibility of cardioreparation (in this case) in elderly rats with advanced HHD, the functional significance of fibrosis, and the regression of cardiac fibrosis, at least in part, through collagenolytic activity. Many questions remain as to the underlying mechanisms by which regression of fibrillar collagen occurs with ACE inhibition. Is it indeed an excess of such inhibitors as bradykinin, nitric oxide, and prostaglandins that activates latent MMPs, and is the expression of MMPs and their natural tissue inhibitors involved? This uncertainty notwithstanding, the potential exists for a cardioreparative intervention to regress or to normalize the adverse structural remodeling by fibrous tissue in HHD and, thereby, to reverse associated functional disturbances.
The cardioreparative concept has now been demonstrated in man15 using a prospective, randomized trial of 35 patients with HHD. In this trial, echocardiographic evidence of LVH with diastolic dysfunction and biopsy-proven left ventricular fibrosis was documented by both morphometric and biochemical assays. No patient had angiographic evidence of coronary artery disease. In a double-blind fashion, patients were randomized to receive either an ACE inhibitor or a thiazide diuretic for 6 months in addition to their preexisting antihypertensive regimen. The study’s primary end point focused on regression of cardiac fibrosis, as determined by biopsy. Only individuals randomized to the ACE inhibitor had a regression in fibrosis. No reduction in LV mass was observed with either regimen. In keeping with the regression in fibrosis, a significant improvement in the echocardiographic parameters of diastolic dysfunction was observed in ACE inhibitor–treated patients.
Overview
This clinical trial by Brilla et al,15 despite its limited size, underscores the potential for targeting adverse structural remodeling in human HHD using a cardioreparative strategy. It supports experimental studies in rats with genetic hypertension showing the potential to regress cardiac fibrosis by ACE inhibition and to reverse ventricular diastolic dysfunction. The study used biopsy tissue to assess cardiac fibrosis directly; this is an invasive methodology with obvious limitations for wide-scale application. Nonetheless, the study findings set the stage for larger trials wherein noninvasive measures of cardiac fibrosis could prove useful. These might include echocardiographic-based characterization of tissue structure16 17 and/or serological markers of collagen turnover.18 19 20 In this connection, Laviades and coworkers18 have reported that ACE inhibitor treatment normalizes such a marker of excess collagen synthesis in patients with HHD.
It is time to revisit the current management of HHD. The importance of pathological structural remodeling must be addressed instead of simply focusing on controlling arterial pressure. In recognizing that the quality, not quantity, of myocardium in HHD is responsible for adverse cardiovascular events, management must not only focus on regression in left ventricular mass. Far more sensible are cardioreparative interventions that specifically target such remodeling with the view toward regressing the same and, in so doing, reducing adverse risk.
Footnotes
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
References
1. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989;13:1637–1652.[Abstract]
2.
Weber KT, Brilla CG. Pathological
hypertrophy and cardiac interstitium: fibrosis and
renin-angiotensin-aldosterone system.
Circulation. 1991;83:1849–1865.
3.
Shapiro LM, McKenna WJ. Left ventricular
hypertrophy: relation of structure to diastolic
function in hypertension. Br Heart J. 1984;51:637–642.
4.
Mulvany MJ. Vascular remodeling of resistance vessels:
can we define this? Cardiovasc Res.. 1999;41:9–13.
5. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1990;115:345–352.
6. Cooper RS, Simmons BE, Castaner A, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol. 1990;65:441–445.[Medline] [Order article via Infotrieve]
7. Weber KT. Angiotensin II and connective tissue: homeostasis and reciprocal regulation. Regul Pept. 1999;82:1–17.[Medline] [Order article via Infotrieve]
8.
Takemoto M, Egashira K, Tomita H, et al. Chronic
angiotensin-converting enzyme inhibition and
angiotensin II type 1 receptor blockade.
Hypertension. 1997;30:1621–1627.
9.
Tomita H, Egashira K, Ohara Y, et al. Early induction
of transforming growth factor-ß via angiotensin II
type I receptors contributes to cardiac fibrosis induced by long-term
blockade of nitric oxide synthesis in rats. Hypertension. 1998;32:273–279.
10.
Emanueli C, Maestri R, Corradi D, et al. Dilated and
failing cardiomyopathy in bradykinin
B2 receptor knockout mice.
Circulation. 1999;100:2359–2365.
11. Factor SM, Flomenbaum M, Zhao MJ, et al. The effects of acutely increased ventricular cavity pressure on intrinsic myocardial connective tissue. J Am Coll Cardiol. 1988;12:1582–1589.[Abstract]
12. Jugdutt BI. Left ventricular rupture threshold during the healing phase after myocardial infarction in the dog. Can J Physiol Pharmacol. 1987;65:307–316.[Medline] [Order article via Infotrieve]
13.
Brilla CG, Janicki JS, Weber KT. Impaired
diastolic function and coronary reserve in genetic
hypertension: role of interstitial fibrosis and medial
thickening of intramyocardial coronary arteries. Circ
Res. 1991;69:107–115.
14.
Brilla CG, Matsubara L, Weber KT. Advanced hypertensive
heart disease in spontaneously hypertensive rats:
lisinopril-mediated regression of myocardial fibrosis.
Hypertension. 1996;28:269–275.
15.
Brilla CG, Funck RC, Rupp H.
Lisinopril-mediated regression of myocardial fibrosis in
patients with hypertensive heart disease. Circulation.. 2000;102:1388–1393.
16.
Picano E, Pelosi G, Marzilli M, et al. In vivo
quantitative ultrasonic evaluation of myocardial fibrosis in humans.
Circulation.. 1990;81:58–64.
17. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr. 1997;10:657–664.[Medline] [Order article via Infotrieve]
18. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens. 1994;7:52–58.[Medline] [Order article via Infotrieve]
19.
Díez J, Laviades C, Mayor G, et al. Increased
serum concentrations of procollagen peptides in essential hypertension:
relation to cardiac alterations. Circulation. 1995;91:1450–1456.
20.
Querejeta R, Varo N, López B, et al. Serum
carboxy-terminal propeptide of procollagen type I is a marker of
myocardial fibrosis in hypertensive heart disease.
Circulation. 2000;101:1729–1735.
This article has been cited by other articles:
 |
|
 |
|
  G. W.-K. Yip, M. Frenneaux, and J. E Sanderson Heart failure with a normal ejection fraction: new developments Heart, October 1, 2009; 95(19): 1549 - 1552. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Campian, H. J. Verberne, M. Hardziyenka, K. de Bruin, M. Selwaness, M. J.B. van den Hoff, J. M. Ruijter, B. L.F. van Eck-Smit, J. M.T. de Bakker, and H. L. Tan Serial Noninvasive Assessment of Apoptosis During Right Ventricular Disease Progression in Rats J. Nucl. Med., August 1, 2009; 50(8): 1371 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pavlopoulos and P. Nihoyannopoulos Regional left ventricular distribution of abnormal segmental relaxation evaluated by strain echocardiography and the incremental value over annular diastolic velocities in hypertensive patients with normal global diastolic function Eur J Echocardiogr, July 1, 2009; 10(5): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Sanderson and G. W K Yip Heart failure with a normal ejection fraction BMJ, January 27, 2009; 338(jan27_1): b52 - b52. [Full Text]
|
|
|
|
|
|
H. Pavlopoulos, J. Grapsa, E. Stefanadi, V. Kamperidis, E. Philippou, D. Dawson, and P. Nihoyannopoulos The evolution of diastolic dysfunction in the hypertensive disease Eur J Echocardiogr, November 1, 2008; 9(6): 772 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Marwick and M. Schwaiger The Future of Cardiovascular Imaging in the Diagnosis and Management of Heart Failure, Part 1: Tasks and Tools Circ Cardiovasc Imaging, July 1, 2008; 1(1): 58 - 69. [Full Text] [PDF]
|
|
|
|
|
|
G W K Yip, M Wang, T Wang, S Chan, J W H Fung, L Yeung, T Yip, S-T Lau, C-P Lau, M-O Tang, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction Heart, May 1, 2008; 94(5): 573 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsuruda, J. Kato, K. Hatakeyama, A. Yamashita, K. Nakamura, T. Imamura, K. Kitamura, T. Onitsuka, Y. Asada, and T. Eto Adrenomedullin in mast cells of abdominal aortic aneurysm Cardiovasc Res, April 1, 2006; 70(1): 158 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuruda, J. Kato, K. Hatakeyama, H. Masuyama, Y.-N. Cao, T. Imamura, K. Kitamura, Y. Asada, and T. Eto Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats Cardiovasc Res, March 1, 2005; 65(4): 921 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Weber From Inflammation to Fibrosis: A Stiff Stretch of Highway Hypertension, April 1, 2004; 43(4): 716 - 719. [Full Text] [PDF]
|
|
|
|
|
|
J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, N. Nishikawa, M. Nishio, T. Ohtani, T. Miwa, M. Hori, and T. Masuyama AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure Hypertension, March 1, 2004; 43(3): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guazzi Alveolar-Capillary Membrane Dysfunction in Heart Failure: Evidence of a Pathophysiologic Role Chest, September 1, 2003; 124(3): 1090 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Boffa, Y. Lu, S. Placier, A. Stefanski, J.-C. Dussaule, and C. Chatziantoniou Regression of Renal Vascular and Glomerular Fibrosis: Role of Angiotensin II Receptor Antagonism and Matrix Metalloproteinases J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1132 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hein, E. Arnon, S. Kostin, M. Schonburg, A. Elsasser, V. Polyakova, E. P. Bauer, W.-P. Klovekorn, and J. Schaper Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms Circulation, February 25, 2003; 107(7): 984 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. F. Bronzwaer, C. Heymes, C. A. Visser, and W. J. Paulus Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H10 - H16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M.C. Dixon A new altruist on the block: effects of adrenomedullin after myocardial infarction Cardiovasc Res, December 1, 2002; 56(3): 347 - 349. [Full Text] [PDF]
|
|
|
|
|
|
T. Walther, A. Schubert, V. Falk, C. Binner, C. Walther, N. Doll, A. Fabricius, S. Dhein, J. Gummert, and F. W. Mohr Left Ventricular Reverse Remodeling After Surgical Therapy for Aortic Stenosis: Correlation to Renin-Angiotensin System Gene Expression Circulation, September 24, 2002; 106(12_suppl_1): I-23 - I-26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hein, W. H. Gaasch, and J. Schaper Giant Molecule Titin and Myocardial Stiffness Circulation, September 10, 2002; 106(11): 1302 - 1304. [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Frangogiannis, S. Shimoni, S. M. Chang, G. Ren, K. Shan, C. Aggeli, M. J. Reardon, G. V. Letsou, R. Espada, M. Ramchandani, et al. Evidence for an Active Inflammatory Process in the Hibernating Human Myocardium Am. J. Pathol., April 1, 2002; 160(4): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Peterson Pressure overload hypertrophy and congestive heart failure: Where is the "Achilles' heel"? J. Am. Coll. Cardiol., February 20, 2002; 39(4): 672 - 675. [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, A. Gonzalez, N. Varo, C. Laviades, R. Querejeta, and J. Diez Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease Hypertension, November 1, 2001; 38(5): 1222 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, R. Querejeta, N. Varo, A. Gonzalez, M. Larman, J. L. Martinez Ubago, and J. Diez Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients Circulation, July 17, 2001; 104(3): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M.C. Dixon Help from within: cardioprotective properties of hepatocyte growth factor Cardiovasc Res, July 1, 2001; 51(1): 4 - 6. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Khalil, A. W. Basher, E. J. Brown Jr, and I. A. Alhaddad A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1757 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.H. Yacoub A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery Eur. Heart J., April 1, 2001; 22(7): 534 - 540. [PDF]
|
|
|
|
 |
|
 J.-J. Boffa, Ying Lu, J.-C. Dussaule, and C. Chatziantoniou Improvements of renal lesions and function by angiotensin and endothelin receptor antagonism in nitric oxide-deficient rats Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S211 - S216. [Abstract] [PDF]
|
|
|
|
|
|
D.-S. Lim, S. Lutucuta, P. Bachireddy, K. Youker, A. Evans, M. Entman, R. Roberts, and A. J. Marian Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy Circulation, February 13, 2001; 103(6): 789 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Boffa, P.-L. Tharaux, J.-C. Dussaule, and C. Chatziantoniou Regression of Renal Vascular Fibrosis by Endothelin Receptor Antagonism Hypertension, February 1, 2001; 37(2): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||